ArticleDiscover oncology2026
EGFL6 predicts unfavorable prognosis and serves as a potential indicator in esophageal carcinoma.
Article in Discover oncology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
Abstract
backgroundThe EGF-like domain multiple 6 (EGFL6) has been documented as an oncogene across diverse cancer types. Despite its known importance in tumorigenesis, EGFL6's involvement in esophageal carcinoma (ESCA) remains largely unexplored. Herein, we integrated multi-source omics data to characterize EGFL6's expression landscape, biological functions, and immunological implications in ESCA-with a focus on its prognostic value.
methodsTo identify dysregulated basement membrane-related genes (BMRGs) in ESCA, we performed Venn overlap analysis on RNA-seq data from The Cancer Genome Atlas (TCGA), Gene Expression Omnibus (GEO), and a curated BMRG reference list. Weighted gene co-expression analysis (WGCNA) was used to identify EGFL6-related modules and functional enrichment of differentially expressed genes (DEGs) were identified via Gene Ontology (GO), Kyoto Encyclopedia of Genes and Genomes (KEGG), and gene set enrichment analysis (GSEA). EGFL6-specific epigenetic (DNA methylation) and genetic alterations were validated using Methsurv and cBioPortal. Single-sample GSEA (ssGSEA) was applied to explore immune infiltration and its correlation with EGFL6. Prognostic significance of EGFL6 was examined via Kaplan-Meier and receiver operating characteristic (ROC) analyses.
resultsVenn overlap analysis indicated EGFL6 as a significantly overexpressed gene in ESCA that closely correlated with multiple clinical and pathological features. WGCNA and subsequent functional enrichment analysis revealed that EGFL6-related DEGs participate in critical biological processes. Kaplan-Meier analysis demonstrated that increased EGFL6 contributed to reduced disease-specific survival (DSS) and progression-free interval (PFI) in patients with ESCA. In vitro experiments confirmed that EGFL6 promotes ESCA by enhancing cell proliferation, invasion and regulating cell-cycle progression.
conclusionEGFL6 is significantly upregulated in ESCA and is related to various clinical factors, immune modulation and reduced prognosis. EGFL6 could be identified as a novel prognostic biomarker and a viable therapeutic target for the development of personalized treatment approaches in ESCA.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.